In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

ClearBridge Growth Strategy highlighted stocks like Vertex Pharmaceuticals Incorporated ... indication in the hopes that altering the future design of its trial will yield more promising results.

Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and precision medicine. With a market cap of $106.1 billion, Vertex ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna’s novel ...

Vertex Pharmaceuticals’ Death Cross signals a bearish trend as shares fall below all critical moving averages. Clinical trial disappointments and technical sell signals pressure VRTX ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia. A Watertown biotech is ...

28,373 people played the daily Crossword recently. Can you solve it faster than others?28,373 people played the daily Crossword recently. Can you solve it faster than others? 30-Year-Old Pours $ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...